Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2012) 29 P538

ICEECE2012 Poster Presentations Diabetes (248 abstracts)

The burden of disease in elderly people with IFG

H. Lutgers 1 , L. Campbell 1, , B. Baune 5 , H. Brodaty 3 , J. Trollor 3 , P. Sachdev 3, & K. Samaras 1,

1Garvan Institute of Medical Research, Darlinghurst, Sydney, NSW, Australia; 2St. Vincent’s Hospital, Darlinghurst, Sydney, NSW, Australia; 3University of New South Wales, Randwick, NSW, Australia; 4Prince of Wales Hospital, Randwick, NSW, Australia; 5Prince of Wales Hospital, Randwick, NSW, Australia; University of Adelaide, Adelaide, SA, Australia.

Introduction: The prevalence of impaired fasting glucose (IFG) in the elderly approaches 50% in some community-dwelling cohorts. We examined whether IFG is associated with a higher burden of disease, cardiovascular risk factors and circulating low-grade inflammation than in normoglycemic elderly people.

Methods/Design: Cross-sectional data of 929 participants of the Sydney Memory and Aging Study (MAS) were examined. MAS is a population-derived cohort of community-dwelling adults aged 70–90 years. Normoglycemic (NG) and IFG participants were compared using contingency tables and the Chi-square test. Logistic regression and ANCOVA analyses were performed adjusted for age, sex and Body Mass Index (BMI).

Results: Mean age was 78.6 (±4.7) years; 47% had IFG, 12% had diagnosed type 2 diabetes and 4% previously undiagnosed type 2 diabetes. There were proportionately more males with IFG compared to NG (49% vs 37% males, P<0.001). As expected, BMI was higher in IFG compared to NG subjects (27.4 kg/m2 vs 26.1 kg/m2, P<0.001). Hypertension and hyperlipidemia was equally distributed (62% and 60% in IFG vs. 57% and 56% in NG), although lipid-lowering drugs had been more frequently prescribed in IFG (55% vs 42%, P<0.001). After adjustment for covariates, rates of stroke, cardiac disease, myocardial infarction, kidney disease or any cancer were similar between participants with IFG and normal fasting glucose. However, PAI-1 (83.7 vs. 79.8 ng/ml, P<0.05), IL-8 (21.8 vs. 18.6 pg/ml, P<0.01), IL-12p70 (3.64 vs 3.40 pg/ml, P<0.05) and products of oxidative metabolism (urate [0.35 vs. 0.32 mmol/l, P<0.001] and malondialdehyde [13.4 vs. 12.8 μmol/l, P<0.001]), were all significantly higher in IFG.

Conclusion: In this cohort of community-dwelling elderly, IFG was not associated with an increased burden of disease cross-sectionally. Prospective data are required to elucidate whether the moderately increased markers of inflammation accompanying IFG in this population adversely affect health outcomes during residual life span.

Declaration of interest: The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research project.

Funding: This work was supported, however funding details unavailable.

Volume 29

15th International & 14th European Congress of Endocrinology

European Society of Endocrinology 

Browse other volumes

Article tools

My recent searches

No recent searches.

My recently viewed abstracts